Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance

Danish Medical Journal

Volumn 61, Issue 7, 2014, Pages

  Højlund, Kurt ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE; INSR PROTEIN, HUMAN; INSULIN; INSULIN RECEPTOR; LEUKOCYTE ANTIGEN; SLC2A4 PROTEIN, HUMAN;

FEMALE; GENETICS; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPID METABOLISM; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADIPONECTIN; ANTIGENS, CD; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; GLYCOGEN SYNTHASE; HUMANS; HYPOGLYCEMIA; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MUSCLE, SKELETAL; OBESITY; POLYCYSTIC OVARY SYNDROME; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84905454646     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (416)

1. Reaven GM. Insulin: the link between obesity and cardiovascular disease. Endocrinol Metab Clin North Am. 2008; 37: 581-601
2. Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am. 2008; 37: 603-21
3. Flakoll P, Carlson MG, Cherrington A. Physiologic action of insulin. In Diabetes Mellitus: A fundamental and clinical text, 3rd ed. LeRoith D, Taylor SI, Olefsky JM, Eds, Lippincott Williams & Wilkins, Philadelphia, 2004, pp 165-82
4. Brehm A, Roden M. Glucose clamp techniques. In Clinical Diabetes Research: Methods and techniques. Roden M (editor). Wiley, London, UK, 2007, pp 43-76
5. Moller DE. Clinical syndromes associated with insulin resistance. In Diabetes Mellitus: A fundamental and clinical text, 2nd ed. LeRoith D, Taylor SI, Olefsky JM, Eds. Lippincott-Raven Publishers, Philadelphia, 1996, pp 584-95
6. Hegele RA. Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends Endocrinol Metab. 2003; 14: 371-7
7. Tan K, Kimber WA, Luan J, Soos MA, Semple RK, Wareham NJ, O'Rahilly S, Barroso I. Analysis of genetic variation in Akt2/PKB-beta in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes. Diabetes. 2007; 56: 714-9
8. Hojlund K, Gaster M, Beck-Nielsen H. Tissue biopsies in diabetes research. In Clinical Diabetes Research: Methods and techniques. Roden M, ed. Wiley, London, UK, 2007, pp 265-88
9. Leroith D, Accili D. Mechanisms of disease: using genetically altered mice to study concepts of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008; 4: 164-72
10. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007; 28: 463-91
11. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008; 7: 95-6
12. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105: 311-20
13. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selectiveresistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999; 104: 447-57
14. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008; 7: 125-34
15. Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, Soos MA, Carpenter TA, Lomas DJ, Cochran EK, Gorden P, O'Rahilly S, Savage DB. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009; 119: 315-22
16. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am. 2008; 37: 635-46
17. Hojlund K, Poulsen M, Stahr P, Bruusgaard K and Beck-Nielsen H. Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes. Eur J Clin Invest. 2002; 32: 918-23
18. Gaster M, Petersen I, Hojlund K, Poulsen P and Beck-Nielsen H. The diabetic phenotype is conserved in myotubes established from diabetic subjects: Evidence for primary defects in glucose transport and glycogen synthase activity. Diabetes. 2002; 51: 921-927
19. Hojlund K, Stahr P, Hansen BF, Green KA, Hardie DG, Ricther EA, Beck-Nielsen H and Wojtazsewski JFP. Increased phosphorylation of skeletal muscle glycogen synthase at NH2-terminal sites during physiological hyperinsulinemia in type 2 diabetes. Diabetes. 2003; 52: 1393-402
20. Gaster M, Brusgaard K, Handberg A, Hojlund K, Wojtazsewski JFP, Beck-Nielsen H. The primary defect in glycogen synthase activity is not based on increased glycogen synthase kinase-3alpha activity in diabetic myotubes. Biochem Biophys Res Com. 2004; 319: 1235-1240
21. Hojlund K, Hansen T, Lajer M, Henriksen JE, Levin K, Lindholm J, Pedersen O, Beck-Nielsen H. A novel syndrome of autosomal dominant hyperinsulinemic hypoglycemia linked to a mutation in the human insulin receptor gene. Diabetes 2004; 53: 1592-8
22. Hojlund K, Birk J, Hansen BF, Vestergaard H, Wojtazsewski JFP, Beck-Nielsen H. Partial Rescue of In Vivo Insulin Signalling in Skeletal Muscle by Impaired Insulin Clearance in Heterozygote Carriers of a Mutation in the Insulin Receptor. Diabetologia. 2006: 49; 1827-37
23. Hojlund K, Beck Nielsen H. Impaired glycogen synthase activity and mitochondrial dysfunction in skeletal muscle. Markers or mediators of insulin resistance in type 2 diabetes. Curr Diabetes Rev. 2006; 2: 375-95
24. Glintborg D, Hojlund K, Andersen NR, Falck Hansen B, Beck-Nielsen H, Wojtaszewski JFP. Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with in polycystic ovary syndrome is reversed by pioglitazone treatment. J Clin Endocrinol Metab. 2008; 93: 3618-26
25. Hojlund K, Glintborg D, Andersen NR, Birk JB, Treebak JT, Frosig C, Beck-Nielsen H, Wojtaszewski JP. Impaired insulinstimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes. 2008; 57: 357-66
26. Hojlund K, Birk JB, Klein DK, Levin K, Rose AJ, Hansen BF, Nielsen JN, Beck-Nielsen H, Wojtaszewski JF. Dysregulation of glycogen synthase COOH-and NH2-terminal phosphorylation by insulin in obesity and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009; 94: 4547-56
27. Hojlund K, Mustard KJ, Staehr P, Hardie DG, Beck-Nielsen H, Richter EA and Wojtazsewski JFP. AMPK activity and isoform protein ekspression are similar in muscle of obese subjects with and without type 2 diabetes. Am J Physiol Endocrinol Metab. 2004; 286: E239-44
28. Hojlund K, Frystyk J, Levin K, Flyvbjerg A, Wojtaszewski JFP, Beck-Nielsen H. Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia. 2006; 49: 1283-91
29. Glintborg D, Frystyk J, Hojlund K, Andersen KK, Henriksen JE, Hermann AP, Hagen C, Flyvbjerg A, Andersen M. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol. 2008; 68: 165-74
30. Hulstrom V, Hojlund K, Vinten J, Beck-Nielsen H, Levin K. Adiponectin and its response to thiazolidinediones are associated with insulin-mediated glucose metabolism in type 2 diabetic patients and their first-degree relatives. Diabetes Obes Metab. 2008; 10: 1019-28
31. Mogensen M, Sahlin K, Fernstrom M, Glintborg D, Beck-Nielsen, Hojlund K. Mitochondrial respiratory function is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes. 2007: 56; 1592-9
32. Bostrom P, Andersson L, Vind B, Haversen L, Rutberg M, Wikstrom Y, Larsson E, Jansson PA, Svensson MK, Branemark R, Ling C, Beck-Nielsen H, Boren J, Hojlund K, Olofsson SO. The SNARE protein SNAP23 and the SNARE interacting protein Munc18c in human skeletal muscle are implicated in insulin sensitivity. Diabetes. 2010; 59: 1870-8
33. Hojlund K, Mogensen M, Sahlin K, Beck-Nielsen H. Mitochondrial dysfunction in Diabetes and Obesity. Endocrinol Metab Clin North Am. 2008; 3: 713-31
34. Hojlund K, Wrzesinski K, Larsen PM, Fey SJ, Roepstorff P, Handberg A, Dela F, Vinten J, McCormack JG, Reynet C, Beck-Nielsen H. Proteome analysis reveals phosphorylation ATP synthase beta-subunit in human skeletal muscle and proteins with potential roles in type 2 diabetes. J Biol Chem. 2003; 278: 10436-42
35. Vind BF, Pehmoller C, Treebak JT, Birk JB, Hey-Mogensen M, Beck-Nielsen H, Zierath JR, Wojtaszewski JFP, Hojlund K. Impaired insulin-induced site-specific phosphorylation of TBC1D4 in skeletal muscle in type 2 diabetes is rescued by endurance exercise training. Diabetologia. 2011; 54: 157-67
36. Højlund K, Yi Z, Lefort N, Langlais P, Bowen B, Levin K, Beck-Nielsen H, Mandarino LJ. Human ATP Synthase βis phosphorylated at multiple sites and shows abnormal phosphorylation at specific sites in insulin resistant muscle. Diabetologia. 2010; 53: 541-51
37. Højlund K, Beck-Nielsen H, Flyvbjerg A, Frystyk J. Characterisation of adiponectin multimers and the IGF axis in humans with a heterozygote mutation in the tyrosine kinase domain of the insulin receptor gene. Eur J Endocrinol. 2012; 166: 511-9
38. Skov V, Glintborg D, Knudsen S, Jensen T, Kruse TA, Tan Q, Brusgaard K, Beck-Nielsen H, Hojlund K. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes. 2007; 56: 2349-55
39. Skov V, Glintborg D, Knudsen S, Tan Q, Jensen T, Kruse T, Beck-Nielsen H, Hojlund K. Pioglitazone enhances expression of genes involved in mitochondrial oxidative metabolism and ribosomal protein biosynthesis in skeletal muscle of women with polycystic ovary syndrome. PLoS One. 2008 3: e2466
40. Vind BF, Birk JB, Vienberg SG, Andersen B, Beck-Nielsen H, Wojtaszewski JF, Hojlund K. Hyperglycaemia normalises insulin action on glucose metabolism but not the impaired activation of AKT and glycogen synthase in the skeletal muscle of patients with type 2 diabetes. Diabetologia. 2012; 55: 1435-45
41. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010; 363(24): 2339-50
42. Drong AW, Lindgren CM, McCarthy MI. The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther. 2012; 92: 707-15
43. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005, 352: 1223-36
44. Qi L, Cho YA. Gene-environment interaction and obesity. Nutr Rev. 2008; 66: 684-94
45. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet. 2005; 6: 221-34
46. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-53
47. Newman B, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD. Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. Diabetologia. 1987; 30: 763-8
48. Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance--a population-based twin study. Diabetologia. 1999; 42:c139-45
49. Kobberling J, Tillil H. Empirical risk figures for first degree relatives of non-insulin dependent diabetics. In The Genetics of Diabetes Mellitus. J. Kobberling and Tattersall, editors. Academic Press, London and New York, 1982, 202-9
50. Haas T, Svacina S, Pav J, Hovorka R, Sucharda P, Sonka J. Risk calculation of type 2 diabetes. Comput Methods Programs Biomed. 1994; 41: 297-303
51. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992; 340: 925-9
52. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest. 1994; 94: 1714-21
53. DeFronzo RA, Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988; 37: 667-87
54. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003; 46: 3-19
55. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med. 1988; 318: 1217-25
56. Warram JH, Martin BC, Krolweski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990; 113: 909-15
57. Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest. 1995; 95: 690-8
58. Vaag A, Henriksen JE, Beck-Nielsen H. Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1992; 89: 782-8
59. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989; 321: 337-43
60. Schalin-Jantti C, Harkonen M, Groop LC. Impaired activation of glycogen synthase in people at increased risk for developing NIDDM. Diabetes. 1992; 41: 598-604
61. Schmitz O, Porksen N, Nyholm B, Skjaerbaek C, Butler PC, Veldhuis JD, Pincus SM. Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. Am J Physiol. 1997; 272: E218-26
62. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA. 1995; 273: 1855-61
63. Tripathy D, Eriksson KF, Orho-Melander M, Frederiksson J, Ahlqvist G, Groop L. Parallel insulin resistance and beta cell decompensation in Type 2 diabetes. Diabetologia. 2004; 47: 782-93
64. Reusch JE, Draznin BB. Atherosclerosis in diabetes and insulin resistance. Diabetes Obes Metab. 2007; 9: 455-63
65. The ADVANCE Collaborative Group*. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008; 358: 2560-72
66. The Action to Control Cardiovascular Risk in Diabetes Study Group*. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008; 358: 2545-59
67. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009; 360: 129-39
68. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008; 359: 1577-89
69. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, Andersen G, et al. Metaanalysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008; 40: 638-45
70. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010; 42: 579-89
71. Grarup N, Sparso T, Hansen T. Physiologic characterization of type 2 diabetes-related loci. Curr Diab Rep. 2010; 10: 485-97
72. Haslam DW, James WP. Obesity. Lancet. 2005; 366: 1197-209
73. Lidofsky SD, Nonalcoholic Fatty Liver Disease: Diagnosis and Relation to Metabolic Syndrome and Approach to Treatment, Curr Diab Rep. 2008; 8: 25-30
74. Flegal KM, Graubard BI, Williamson DF, Gail MH. Causespecific excess deaths associated with underweight, overweight, and obesity. JAMA. 2007; 298: 2028-37
75. Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, Ferrannini E. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes. 2000; 49: 1367-73
76. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA; San Antonio metabolism study. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia. 2004; 47: 31-9
77. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997; 100: 1166-73
78. McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med. 2007; 167: 642-8
79. Atwood LD, Heard-Costa NL, Cupples LA, Jaquish CE, Wilson PW, D'Agostino RB. Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. Am J Hum Genet. 2002; 71: 1044-50
80. Mutch DM, Clement K. Unraveling the genetics of human obesity. PLoS Genet. 2006; 2: e188
81. Willer CJ, Speliotes EK, Loos RJ, Li S, Lindgren CM, Heid IM, Berndt SI, Elliott AL, Jackson AU, Lamina C, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet. 2009; 41: 25-34
82. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A, Styrkarsdottir U, Gretarsdottir S, Thorlacius S, Jonsdottir I, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet. 2009; 41: 18-24
83. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Lango Allen H, Lindgren CM, Luan J, Magi R, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010; 42: 937-48
84. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33: 981-1030
85. Glintborg D, Hermann AP, Andersen M, Hagen C, Beck-Nielsen H, Veldhuis JD, Henriksen JE. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril. 2006; 86: 385-397
86. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989; 38: 1165-74
87. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999; 22: 141-6
88. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84: 165-9
89. Sathyapalan T, Atkin SL. Recent advances in cardiovascular aspects of polycystic ovary syndrome. Eur J Endocrinol. 2012; 166: 575-83
90. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995; 96: 520-7
91. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996; 81: 942-7
92. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992; 41: 1257-66
93. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998; 83: 2001-5
94. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991; 72: 83-9
95. Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007; 3: 103-11
96. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, Li Z, You L, Zhao J, Liu J, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011; 43: 55-9
97. Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, Zhang B, Liang X, Li T, Chen J, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012; 44: 1020-5
98. Taylor SI, Oral AE, Accili D. Genetic syndromes associated with severe insulin resistance. Mutations in the insulin receptor gene and lipoapotrophic diabetes. In Diabetes Mellitus: A fundamental and clinical text, 3rd ed. LeRoith D, Taylor SI, Olefsky JM, Eds, Lippincott Williams & Wilkins, Philadelphia, 2004, pp 1013-1028
99. Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes. 1992; 41: 1473-90
100. Moller DE, Cohen O, Yamaguchi Y, Assiz R, Grigorescu F, Eberle A, Morrow LA, Moses AC, Flier JS: Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes. 1994; 43: 247-255
101. Krook A, Kumar S, Laing I, Boulton AJ, Wass JA, O'Rahilly S: Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes. 1994; 43: 357-368
102. Maassen JA, Tobias ES, Kayserilli H, Tukel T, Yuksel-Apak M, D'Haens E, Kleijer WJ, Fery F, van der Zon GC. Identification and functional assessment of novel and known insulin receptor mutations in five patients with syndromes of severe insulin resistance. J Clin Endocrinol Metab. 2003; 88: 4251-7
103. Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004; 83: 209-22
104. Vinik AI, Seino S, Funakoshi A, Schwartz J, Matsumoto M, Schteingart DE, Fu Z, Tsai S: Familial hyperinsulinaemia associated with secretion of an abnormal insulin, and coexistenceof insulin resistance in the propositus. J Clin Endocrinol Metab. 1986; 62: 645-52
105. Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J: Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science. 1995; 268: 426-29
106. Thomas P, Ye Y, Lightner E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet. 1996; 5: 1809-12
107. Dunne MJ, Kane C, Shepherd RM, Sanchez JA, James RFL, Johnson PRV, Aynsley-Green A, Lu S, Clement IV JP, Lindley KJ, Seino S, Aguilar-Bryan L: Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. N Engl J Med. 1997; 336: 703-6
108. Stanley CA, Lieu YK, Hsu BYL, Burlina AB, Greenberg CR, Hopwood NJ, Perlman K, Rich BH, Zammarchi E, Poncz M: Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med. 1998; 338: 1352-57
109. Moritz W, Froesch ER, Boni-Schnetzler M: Functional properties of a heterozygous mutation (Arg1174-->Gln) in the tyrosine kinase domain of the insulin receptor from a type A insulin resistant patient. FEBS Lett. 1994; 351: 276-80
110. Kitamura T, Kahn CR, Accili D. Insulin receptor knockout mice. Annu Rev Physiol. 2003; 65: 313-332
111. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF, Accili D. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest. 2000; 105: 199-205
112. Bruning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell. 1997; 88: 561-72
113. Pai JK, Cahill LE, Hu FB, Rexrode KM, Manson JE, Rimm EB. Hemoglobin a1c is associated with increased risk of incident coronary heart disease among apparently healthy, nondiabetic men and women. J Am Heart Assoc. 2013; 2: e000077
114. Beck-Nielsen H. Mechanisms of insulin resistance in nonoxidative glucose metabolism: the role of glycogen synthase. J Basic Clin Physiol Pharmacol. 1998; 9: 255-79
115. Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites of non-insulin-and insulin-mediated glucose uptake in humans. Am J Physiol. 1988; 255: E769-74
116. Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest. 1994; 94: 2349-56
117. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 1990; 322: 223-8
118. Adams JM 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC,Mandarino LJ. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes. 2004; 53: 25-31
119. Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J. 1999; 13: 2051-60
120. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest. 1999; 104: 733-41
121. Damsbo P, Vaag A, Hother-Nielsen O, Beck-Nielsen H. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulindependent) diabetes mellitus. Diabetologia. 1991; 34: 239-45
122. Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA. Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes. 2002; 51: 462-8
123. Simoneau JA, Kelley DE. Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. J Appl Physiol. 1997; 83: 166-71
124. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes. 2000; 49: 677-83
125. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol. 1999; 277: E1130-41
126. Morin-Papunen 2000 Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod. 2000; 15: 1266-74
127. Svendsen PF, Nilas L, Norgaard K, Jensen JE, Madsbad S. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. Hum Reprod. 2008; 23: 2113-21
128. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Caruso A, Mancuso S, Lanzone A. Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod. 1997; 12: 1897-901
129. Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, Fanta M, Vondra K, Skrha J. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89: 2942-5
130. Dunaif A, Sorbara L, Delson R, Green G. Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes. 1993; 42: 1462-8
131. Beeson M, Sajan MP, Daspet JG, Luna V, Dizon M, Grebenev D, Powe JL, Lucidi S, Miura A, Kanoh Y, Bandyopadhyay G, Standaert ML, Yeko TR, Farese RV. Defective Activation of Protein Kinase C-z in Muscle by Insulin and Phosphatidylinositol-3,4,5,-(PO(4))(3) in Obesity and Polycystic Ovary Syndrome. Metab Syndr Relat Disord. 2004; 2: 49-56
132. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 1987; 65: 499-507
133. Vestergaard H, Klein HH, Hansen T, Muller J, Skovby F, Bjorbaek C, Roder ME, Pedersen O. Severe insulin-resistant diabetes mellitus in patients with congenital muscle fiber type disproportion myopathy. J Clin Invest. 1995; 95: 1925-32
134. Huang Z, Li Y, Tang T, Xu W, Liao Z, Yao B, Hu G, Weng J. Hyperinsulinaemic hypoglycaemia associated with a heterozygous missense mutation of R1174W in the insulin receptor (IR) gene. Clin Endocrinol (Oxf). 2009; 71: 659-65
135. Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag A. Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes. 2005; 54: 275-83
136. Rothman DL, Magnusson I, Cline G, Gerard D, Kahn CR, Shulman RG, Shulman GI. Decreased muscle glucose transport/ phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A. 1995; 92: 983-7
137. Nikoulina S, Cieraldi TP, Abrams-Carter L, Mudaliar S, Park KS, Henry RR. Regulation of glycogen synthase in cultured skeletal muscle cells from subjects with Type II diabetes. Role of chronic hyperinsulinemia and hyperglycemia. Diabetes. 1997; 46: 1017-24
138. McIntyre EA, Halse R, Yeaman SJ, Walker M. Cultured muscle cells from insulin-resistant type 2 diabetes patients have impaired insulin, but normal 5-amino-4-imidazolecarboxamide riboside-stimulated, glucose uptake. J Clin Endocrinol Metab. 2004; 89: 3440-48
139. Storgaard H, Song XM, Jensen CB, Madsbad S, Bjornholm M, Vaag A, Zierath JR. Insulin signal transduction in skeletal muscle from glucose-intolerant relatives of type 2 diabetic patients. Diabetes. 2001; 50: 2770-8
140. Niskanen L, Sarlund H, Laakso M. Metabolic defects in persistent impaired glucose tolerance are related to the family history of non-insulin-dependent diabetes mellitus. Metabolism. 1995; 44: 1099-104
141. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995; 80: 2586-93
142. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963; 1: 785-9
143. Kelley DE, Mandarino LJ. Hyperglycemia normalizes insulinstimulated skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus. J Clin Invest. 1990; 86: 1999-2007
144. Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest. 2005; 115: 1699-702
145. Ukropcova B, Sereda O, de Jonge L, Bogacka I, Nguyen T, Xie H, Bray GA, Smith SR. Family history of diabetes links impaired substrate switching and reduced mitochondrial content in skeletal muscle. Diabetes. 2007; 56: 720-7
146. Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003; 111: 121-4
147. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999; 103: 253-9
148. Winder WW, Arogyasami J, Elayan IM, Cartmill D. Time course of exercise-induced decline in malonyl-CoA in different muscle types. Am J Physiol. 1990; 259: E266-71
149. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999; 277: E1-E10
150. Bandyopadhyay GK, Yu JG, Ofrecio J, Olesky JM. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes. 2006; 55: 2277-85
151. Hulver MW, Dohm GL. The molecular mechanism linking muscle fat accumulation to insulin resistance. Proc Nutr Soc. 2004; 63: 375-80
152. Krebs M, Roden M. Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature. Diabetes Obes Metab. 2005; 7: 621-32
153. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002; 51: 7-18
154. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB, Storlien LH. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997; 46: 983-8
155. Phillips DI, Caddy S, Ilic V, Fielding BA, Frayn KN, Borthwick AC, Taylor R. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism. 1996; 45: 947-50
156. He J, Watkins S, Kelley DE. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes. 2001; 50: 817-23
157. Levin K, Daa Schroeder H, Alford FP, Beck-Nielsen H. Morphometric documentation of abnormal intramyocellular fat storage and reduced glycogen in obese patients with Type II diabetes. Diabetologia. 2001; 44: 824-33
158. Nielsen J, Mogensen M, Vind BF, Sahlin K, Hojlund K, Schroder HD, Ortenblad N. Increased subsarcolemmal lipids in type 2 diabetes: effect of training on localization of lipids, mitochondria, and glycogen in sedentary human skeletal muscle. Am J Physiol Endocrinol Metab. 2010; 298: E706-13
159. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD, Haring HU. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes. 1999; 48: 1113-9
160. Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW, Cooney GJ. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab. 2000; 279: E554-60
161. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaBalpha. Diabetes. 2002; 51: 2005-11
162. Thrush AB, Brindley DN, Chabowski A, Heigenhauser GJ, Dyck DJ. Skeletal muscle lipogenic protein expression is not different between lean and obese individuals: a potential factor in ceramide accumulation. J Clin Endocrinol Metab. 2009; 94: 5053-61
163. Itani SI, Zhou Q, Pories WJ, MacDonald KG, Dohm GL. Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes. 2000; 49: 1353-8
164. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000; 106: 171-6
165. Ahmad Z, Lee FT, DePaoli-Roach A, Roach PJ. Phosphorylation of glycogen synthase by the Ca2+-and phospholipidactivated protein kinase (protein kinase C). J Biol Chem. 1984; 259: 8743-7
166. Avignon A, Yamada K, Zhou X, Spencer B, Cardona O, Saba-Siddique S, Galloway L, Standaert ML, Farese RV. Chronic activation of protein kinase C in soleus muscles and other tissues of insulin-resistant type II diabetic Goto-Kakizaki (GK), obese/aged, and obese/Zucker rats. A mechanism for inhibiting glycogen synthesis. Diabetes. 1996; 45: 1396-404
167. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2011; 8: 92-103
168. Hwang H, Bowen B, Lefort N, Flynn CR, De Filippis EA, Roberts C, Smoke CC, Meyer C, Hojlund K, Yi Z, Mandarino LJ. Proteomics Analysis of Human Skeletal Muscle Reveals Novel Abnormalities in Obesity and Type 2 Diabetes Mellitus. Diabetes. 2010; 59: 33-42
169. Snogdal LS, Wod M, Grarup N, Vestmar M, Sparso T, Jorgensen T, Lauritzen T, Beck-Nielsen H, Henriksen JE, Pedersen O, Hansen T, Hojlund K. Common variation in oxidative phosphorylation genes is not a major cause of insulin resistance or type 2 diabetes. Diabetologia. 2012; 55: 340-8
170. Giebelstein J, Poschmann G, Hojlund K, Schechinger W, Dietrich JW, Levin K, Beck-Nielsen H, Podwojski K, Stuhler K, Meyer HE, Klein HH. The proteomic signature of insulinresistant human skeletal muscle reveals increased glycolytic and decreased mitochondrial enzymes. Diabetologia. 2012; 55: 1114-27
171. Lefort N, Glancy B, Bowen B, Willis WT, Bailowitz Z, De Filippis EA, Brophy C, Meyer C, Hojlund K, Yi Z, Mandarino LJ. Increased ROS production and lower abundance of complex I subunits and carnitine plamitoyltransferase protein despite normal mitochondrial respiration in insulin resistant human skeletal muscle. Diabetes. 2010; 59: 2444-52
172. Zhao X, Leon IR, Wrzesinski K, Mogensen M, Bak S, Hojlund K, Jensen ON. Phosphoproteome analysis of functional mitochondria isolated from resting human muscle reveals extensive phosphorylation of inner membrane protein complexes and enzymes. Mol Cell Proteomics. 2011; 10: M110.000299
173. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol. 2010; 2010: 476279
174. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest. 1999; 103: 931-43
175. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006; 7: 85-96
176. Cohen P, Alessi DR, Cross DA. PDK1, one of the missing links in insulin signal transduction? FEBS Lett. 1997; 410: 3-10
177. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes. 2006; 55: 2392-7
178. Bouzakri K, Zachrisson A, Al-Khalili L, Zhang BB, Koistinen HA, Krook A, Zierath JR. siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle. Cell Metab. 2006; 4: 89-96
179. Langlais P, Yi Z, Finlayson J, Luo M, Mapes R, De Filippis E, Meyer C, Plummer E, Tongchinsub P, Mattern M, Mandarino LJ. Global IRS-1 phosphorylation analysis in insulin resistance. Diabetologia. 2011; 54: 2878-89
180. Yi Z, Langlais P, De Filippis EA, Luo M, Flynn CR, Schroeder S, Weintraub ST, Mapes R, Mandarino LJ. Global assessment of regulation of phosphorylation of insulin receptor substrate-1 by insulin in vivo in human muscle. Diabetes. 2007; 56: 1508-16
181. Sakamoto K, Holman GD. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab. 2008; 295: E29-37
182. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996; 15: 6541-51
183. Hajduch E, Litherland GJ, Hundal HS. Protein kinase B (PKB/Akt)--a key regulator of glucose transport? FEBS Lett. 2001; 492: 199-203
184. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005; 280: 40406-16
185. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. 2010; 11: 9-22
186. Gonzalez E, McGraw TE. Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proc Natl Acad Sci U S A. 2009; 106: 7004-9
187. Larance M, Ramm G, Stockli J, van Dam EM, Winata S, Wasinger V, Simpson F, Graham M, Junutula JR, Guilhaus M, James DE. Characterization of the role of the Rab GTPaseactivating protein AS160 in insulin-regulated GLUT4 trafficking. J Biol Chem. 2005; 280: 37803-13
188. Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS, Garner CW, Lienhard GE. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem. 2003; 278: 14599-602
189. Zeigerer A, McBrayer MK, McGraw TE. Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. Mol Biol Cell. 2004; 15:4406-15
190. Kramer HF, Witczak CA, Taylor EB, Fujii N, Hirshman MF, Goodyear LJ. AS160 regulates insulin-and contractionstimulated glucose uptake in mouse skeletal muscle. J Biol Chem. 2006; 281:31478-85
191. Geraghty KM, Chen S, Harthill JE, Ibrahim AF, Toth R, Morrice NA, Vandermoere F, Moorhead GB, Hardie DG, MacKintosh C. Regulation of multisite phosphorylation and 14-3-3 binding of AS160 in response to IGF-1, EGF, PMA and AICAR. Biochem J. 2007; 407: 231-41
192. Treebak JT, Taylor EB, Witczak CA, An D, Toyoda T, Koh HJ, Xie J, Feener EP, Wojtaszewski JF, Hirshman MF, Goodyear LJ. Identification of a novel phosphorylation site on TBC1D4 regulated by AMP-activated protein kinase in skeletal muscle. Am J Physiol Cell Physiol. 2010; 298: C377-85
193. Ramm G, Larance M, Guilhaus M, James DE. A Role for 14-3-3 in Insulin-stimulated GLUT4 Translocation through Its Interaction with the RabGAP AS160. J Biol Chem. 2006; 281: 29174-80
194. Treebak JT, Frosig C, Pehmoller C, Chen S, Maarbjerg SJ, Brandt N, MacKintosh C, Zierath JR, Hardie DG, Kiens B, Richter EA, Pilegaard H, Wojtaszewski JF. Potential role of TBC1D4 in enhanced post-exercise insulin action in humanskeletal muscle. Diabetologia. 2009; 52: 891-900
195. Kramer HF, Witczak CA, Fujii N, Jessen N, Taylor EB, Arnolds DE, Sakamoto K, Hirshman MF, Goodyear LJ. Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes. 2006; 55: 2067-76
196. Treebak JT, Glund S, Deshmukh A, Klein DK, Long YC, Jensen TE, Jorgensen SB, Viollet B, Andersson L, Neumann D, Wallimann T, Richter EA, Chibalin AV, Zierath JR, Wojtaszewski JF: AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits. Diabetes. 2006; 55: 2051-8
197. Klip A. The many ways to regulate glucose transporter 4. Appl Physiol Nutr Metab. 2009; 34: 481-7
198. Sun Y, Bilan PJ, Liu Z, Klip A. Rab8A and Rab13 are activated by insulin and regulate GLUT4 translocation in muscle cells. Proc Natl Acad Sci U S A. 2010; 107: 19909-14
199. Chiu TT, Jensen TE, Sylow L, Richter EA, Klip A. Rac1 signalling towards GLUT4/glucose uptake in skeletal muscle. Cell Signal. 2011; 23: 1546-54
200. JeBailey L, Rudich A, Huang X, Di Ciano-Oliveira C, Kapus A, Klip A. Skeletal muscle cells and adipocytes differ in their reliance on TC10 and Rac for insulin-induced actin remodeling. Mol Endocrinol. 2004; 18: 359-72
201. Sylow L, Jensen TE, Kleinert M, Hojlund K, Kiens B, Wojtaszewski J, Prats C, Schjerling P, Richter EA. Rac1 signaling is required for insulin-stimulated glucose uptake and is dysregulated in insulin resistant murine and human skeletal muscle. Diabetes. 2013 Feb 19. [Epub ahead of print]
202. Foster LJ, Weir ML, Lim DY, Liu Z, Trimble WS, Klip A. A functional role for VAP-33 in insulin-stimulated GLUT4 traffic. Traffic. 2000; 1: 512-21
203. Brandie FM, Aran V, Verma A, McNew JA, Bryant NJ, Gould GW. Negative regulation of syntaxin4/SNAP-23/VAMP2-mediated membrane fusion by Munc18c in vitro. PLoS One. 2008; 3: e4074
204. Foley K, Boguslavsky S, Klip A. Endocytosis, recycling, and regulated exocytosis of glucose transporter 4. Biochemistry. 2011; 50: 3048-61
205. Sylow L, Jensen TE, Kleinert M, Mouatt JR, Maarbjerg SJ, Jeppesen J, Prats C, Chiu TT, Boguslavsky S, Klip A, Schjerling P, Richter EA. Rac1 is a novel regulator of contractionstimulated glucose uptake in skeletal muscle. Diabetes. 2013; 62: 1139-51
206. Lawrence JC Jr, Roach PJ. New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes. 1997; 46: 541-7
207. Villar-Palasi C, Guinovart JJ. The role of glucose 6-phosphate in the control of glycogen synthase. FASEB J. 1997;11:544-58
208. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS. Glycogen and its metabolism: some new developments and old themes. Biochem J. 2012; 441: 763-87
209. Thomas JA, Schlender KK, Larner J. A rapid filter paper assay for UDP-glucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose. Anal Biochem. 1968; 25: 486-99
210. Richter EA, Mikines KJ, Galbo H, Kiens B. Effect of exercise on insulin action in human skeletal muscle. J Appl Physiol. 1989; 66: 876-85
211. Parker PJ, Caudwell FB, Cohen P. Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. Eur J Biochem. 1983; 130: 227-34
212. Poulter L, Ang SG, Gibson BW, Williams DH, Holmes CF, Caudwell FB, Pitcher J, Cohen P. Analysis of the in vivo phosphorylation state of rabbit skeletal muscle glycogen synthase by fast-atom-bombardment mass spectrometry. Eur J Biochem. 1988; 175: 497-510
213. Skurat AV, Dietrich AD, Roach PJ. Glycogen synthase sensitivity to insulin and glucose-6-phosphate is mediated by both NH2-and COOH-terminal phosphorylation sites. Diabetes. 2000; 49: 1096-100
214. Prats C, Helge JW, Nordby P, Qvortrup K, Ploug T, Dela F, Wojtaszewski JF. Dual regulation of muscle glycogen synthase during exercise by activation and compartmentalization. J Biol Chem. 2009; 284: 15692-700
215. Roach PJ. Multisite and hierarchal protein phosphorylation. J Biol Chem 1991;266:14139-42
216. Picton C, Woodgett J, Hemmings B, Cohen P. Multisite phosphorylation of glycogen synthase from rabbit skeletal muscle. Phosphorylation of site 5 by glycogen synthase kinase-5 (casein kinase-II) is a prerequisite for phosphorylation of sites 3 by glycogen synthase kinase-3. FEBS Lett. 1982; 150: 191-6
217. Zhang W, DePaoli-Roach AA, Roach PJ. Mechanisms of multisite phosphorylation and inactivation of rabbit muscle glycogen synthase. Arch Biochem Biophys. 1993; 304: 219-25
218. Skurat AV, Dietrich AD. Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family protein kinases. J Biol Chem. 2004; 279: 2490-8
219. Kuma Y, Campbell DG, Cuenda A. Identification of glycogen synthase as a new substrate for stress-activated protein kinase 2b/p38beta. Biochem J. 2004; 379: 133-9
220. Carling D, Hardie DG. The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta. 1989; 1012: 81-6
221. Nakielny S, Campbell DG, Cohen P. The molecular mechanism by which adrenalin inhibits glycogen synthesis. Eur J Biochem. 1991; 199: 713-22
222. Ragolia L, Begum N. Protein phosphatase-1 and insulin action. Mol Cell Biochem. 1998; 182: 49-58
223. Cohen PT. Important roles for novel protein phosphatases dephosphorylating serine and threonine residues. Biochem Soc Trans. 1993; 21: 884-8
224. Dent P, Lavoinne A, Nakielny S, Caudwell FB, Watt P, Cohen P. The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature. 1990; 348: 302-8
225. Jensen J, Lai YC. Regulation of muscle glycogen synthase phosphorylation and kinetic properties by insulin, exercise, adrenaline and role in insulin resistance. Arch Physiol Biochem. 2009; 115: 13-21
226. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378: 785-9
227. Cross DA, Watt PW, Shaw M, van der Kaay J, Downes CP, Holder JC, Cohen P. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. FEBS Lett. 1997; 406: 211-5
228. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes. 2000; 49: 263-71
229. Wojtaszewski JF, Hansen BF, Gade J, Kiens B, Markuns JF, Goodyear LJ, Richter EA. Insulin signaling and insulin sensitivity after exercise in human skeletal muscle. Diabetes. 2000; 49: 325-31
230. Lawrence JC Jr, Zhang JN. Control of glycogen synthase and phosphorylase by amylin in rat skeletal muscle. Hormonal effects on the phosphorylation of phosphorylase and on the distribution of phosphate in the synthase subunit. J Biol Chem. 1994; 269: 11595-600
231. Lawrence JC Jr, Hiken JF, DePaoli-Roach AA, Roach PJ. Hormonal control of glycogen synthase in rat hemidiaphragms. J Biol Chem. 1983; 258: 10710-9
232. Aschenbach WG, Suzuki Y, Breeden K, Prats C, Hirshman MF, Dufresne SD, Sakamoto K, Vilardo PG, Steele M, Kim JH, et al. The muscle-specific protein phosphatase PP1G/R(GL)(G(M)) is essential for activation of glycogen synthase by exercise.J Biol Chem. 2001; 276: 39959-67
233. Suzuki Y, Lanner C, Kim JH, Vilardo PG, Zhang H, Yang J, Cooper LD, Steele M, Kennedy A, Bock CB, et al. Insulin control of glycogen metabolism in knockout mice lacking the musclespecific protein phosphatase PP1G/RGL. Mol Cell Biol. 2001; 21: 2683-94
234. Walker KS, Watt PW, Cohen P. Phosphorylation of the skeletal muscle glycogen-targetting subunit of protein phosphatase 1 in response to adrenaline in vivo. FEBS Lett. 2000; 466: 121-4
235. Delibegovic M, Armstrong CG, Dobbie L, Watt PW, Smith AJ, Cohen PT. Disruption of the striated muscle glycogen targeting subunit PPP1R3A of protein phosphatase 1 leads to increased weight gain, fat deposition, and development of insulin resistance. Diabetes. 2003; 52: 596-604
236. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, Alessi DR. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 2005; 24: 1571-83
237. Bouskila M, Hirshman MF, Jensen J, Goodyear LJ, Sakamoto K. Insulin promotes glycogen synthesis in the absence of GSK3 phosphorylation in skeletal muscle. Am J Physiol Endocrinol Metab. 2008; 294: E28-35
238. Bouskila M, Hunter RW, Ibrahim AF, Delattre L, Peggie M, van Diepen JA, Voshol PJ, Jensen J, Sakamoto K. Allosteric regulation of glycogen synthase controls glycogen synthesis in muscle. Cell Metab. 2010; 12: 456-66
239. Kasuga M, Ogawa W, Ohara T. Tissue glycogen content and glucose intolerance. J Clin Invest. 2003; 111: 1282-4
240. Shulman RG, Rothman DL. Enzymatic phosphorylation of muscle glycogen synthase: a mechanism for maintenance of metabolic homeostasis. Proc Natl Acad Sci U S A. 1996; 93: 7491-5
241. Azpiazu I, Manchester J, Skurat AV, Roach PJ, Lawrence JC Jr. Control of glycogen synthesis is shared between glucose transport and glycogen synthase in skeletal muscle fibers. Am J Physiol Endocrinol Metab. 2000; 278: E234-43
242. Fisher JS, Nolte LA, Kawanaka K, Han DH, Jones TE, Holloszy JO. Glucose transport rate and glycogen synthase activity both limit skeletal muscle glycogen accumulation. Am J Physiol Endocrinol Metab. 2002; 282: E1214-21
243. Beck-Nielsen H. The role of glycogen synthase in the development of hyperglycemia in type 2 diabetes: 'To store or not to store glucose, that's the question'. Diabetes Metab Res Rev. 2012; 28: 635-44
244. Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proenca C, Bacot F, Balkau B, Belisle A, Borch-Johnsen K, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet. 2009; 41: 1110-5
245. Pirola L, Johnston AM, Van Obberghen E. Modulation of insulin action. Diabetologia. 2004; 47: 170-84
246. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes. 2009; 58: 2718-25
247. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012; 13: 239-50
248. Lofman M, Yki-Jarvinen H, Parkkonen M, Lindstrom J, Koranyi L, Schalin-Jantti C, Groop L. Increased concentrations of glycogen synthase protein in skeletal muscle of patients with NIDDM. Am J Physiol. 1995; 269: E27-32
249. Krook A, Bjornholm M, Galuska D, Jiang XJ, Fahlman R, Myers MG Jr, Wallberg-Henriksson H, Zierath JR. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes. 2000; 49: 284-92
250. Vestergaard H, Lund S, Bjorbaek C, Pedersen O. Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control. Diabetologia. 1995; 38: 1230-8
251. Vestergaard H, Lund S, Larsen FS, Bjerrum OJ, Pedersen O. Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscle from insulin-resistant patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1993; 91: 2342-50
252. Ducluzeau PH, Perretti N, Laville M, Andreelli F, Vega N, Riou JP, Vidal H. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes. 2001; 50: 1134-42
253. Tsuchida H, Bjornholm M, Fernstrom M, Galuska D, Johansson P, Wallberg-Henriksson H, Zierath JR, Lake S, Krook A. Gene expression of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in skeletal muscle from type 2 diabetic subjects. Pflugers Arch. 2002; 445: 25-31
254. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes. 1997; 46: 524-7
255. Pratipanawatr W, Pratipanawatr T, Cusi K, Berria R, Adams JM, Jenkinson CP, Maezono K, DeFronzo RA, Mandarino LJ. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation. Diabetes. 2001; 50: 2572-8
256. Meyer MM, Levin K, Grimmsmann T, Beck-Nielsen H, Klein HH. Insulin signalling in skeletal muscle of subjects with or without Type II-diabetes and first degree relatives of patients with the disease. Diabetologia. 2002; 45: 813-22
257. Garvey WT, Maianu L, Hancock JA, Golichowski AM, Baron A. Gene expression of GLUT4 in skeletal muscle from insulinresistant patients with obesity, IGT, GDM, and NIDDM. Diabetes. 1992; 41: 465-75
258. Andersen PH, Lund S, Vestergaard H, Junker S, Kahn BB, Pedersen O. Expression of the major insulin regulatable glucose transporter (GLUT4) in skeletal muscle of noninsulindependent diabetic patients and healthy subjects before and after insulin infusion. J Clin Endocrinol Metab. 1993; 77: 27-32
259. Pedersen O, Bak JF, Andersen PH, Lund S, Moller DE, Flier JS, Kahn BB. Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes. 1990; 39: 865-70
260. Schalin-Jantti C, Yki-Jarvinen H, Koranyi L, Bourey R, Lindstrom J, Nikula-Ijas P, Franssila-Kallunki A, Groop LC. Effect of insulin on GLUT-4 mRNA and protein concentrations in skeletal muscle of patients with NIDDM and their first-degree relatives. Diabetologia. 1994; 37: 401-7
261. Lund S, Vestergaard H, Andersen PH, Schmitz O, Gotzsche LB, Pedersen O. GLUT-4 content in plasma membrane of muscle from patients with non-insulin-dependent diabetes mellitus. Am J Physiol. 1993; 265: E889-97
262. Handberg A, Vaag A, Damsbo P, Beck-Nielsen H, Vinten J. Expression of insulin regulatable glucose transporters inskeletal muscle from type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1990; 33: 625-7
263. Eriksson J, Koranyi L, Bourey R, Schalin-Jantti C, Widen E, Mueckler M, Permutt AM, Groop LC. Insulin resistance in type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT-4) gene in human skeletal muscle. Diabetologia. 1992; 35: 143-7
264. Karlsson HK, Zierath JR, Kane S, Krook A, Lienhard GE, Wallberg-Henriksson H: Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes. 2005; 54: 1692-7
265. Karlsson HK, Ahlsen M, Zierath JR, Wallberg-Henriksson H, Koistinen HA: Insulin signaling and glucose transport in skeletal muscle from first-degree relatives of type 2 diabetic patients. Diabetes. 2006; 55: 1283-8
266. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013; 152: 673-84
267. Copeland RJ, Bullen JW, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am J Physiol Endocrinol Metab. 2008; 295: E17-28
268. Wells L, Vosseller K, Hart GW. A role for N-acetylglucosamine as a nutrient sensor and mediator of insulin resistance. Cell Mol Life Sci. 2003; 60: 222-8
269. Patti ME, Virkamaki A, Landaker EJ, Kahn CR, Yki-Jarvinen H. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Diabetes. 1999; 48: 1562-71
270. Parker GJ, Lund KC, Taylor RP, McClain DA. Insulin resistance of glycogen synthase mediated by o-linked Nacetylglucosamine. J Biol Chem. 2003; 278: 10022-7
271. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002; 23: 599-622
272. Fridlyand LE, Philipson LH. Reactive species and early manifestation of insulin resistance in type 2 diabetes. Diabetes Obes Metab. 2006; 8: 136-45
273. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 2006; 3: 393-402
274. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148: 852-71
275. Schmitz-Peiffer C. Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann N Y Acad Sci. 2002; 967: 146-57
276. Olofsson SO, Andersson L, Haversen L, Olsson C, Myhre S, Rutberg M, Mobini R, Li L, Lu E, Boren J, Bostrom P. The formation of lipid droplets: possible role in the development of insulin resistance/type 2 diabetes. Prostaglandins Leukot Essent Fatty Acids. 2011; 85: 215-8
277. Leroith D, Accili D. Mechanisms of disease: using genetically altered mice to study concepts of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008; 4:164-72
278. Goren HJ, Kulkarni RN, Kahn CR. Glucose homeostasis and tissue transcript content of insulin signaling intermediates in four inbred strains of mice: C57BL/6, C57BLKS/6, DBA/2, and 129X1. Endocrinology. 2004; 145: 3307-23
279. Berglund ED, Li CY, Poffenberger G, Ayala JE, Fueger PT, Willis SE, Jewell MM, Powers AC, Wasserman DH. Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes. 2008; 57: 1790-9
280. Grimmsmann T, Levin K, Meyer MM, Beck-Nielsen H, Klein HH. Delays in insulin signaling towards glucose disposal in human skeletal muscle. J Endocrinol. 2002; 172: 645-51
281. Wojtaszewski JFP, Hansen BF, Kiens B, Richter EA. Insulin signaling in human skeletal muscle: time course and effect of exercise. Diabetes. 1997; 46: 1775-81
282. Nolan JJ, Ludvik B, Baloga J, Reichart D, Olefsky JM. Mechanisms of the kinetic defect in insulin action in obesity and NIDDM. Diabetes. 1997; 46: 994-1000
283. Caro JF, Sinha MK, Raju SM, Ittoop O, Pories WJ, Flickinger EG, Meelheim D, Dohm GL. Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest. 1987; 79: 1330-7
284. Nolan JJ, Freidenberg G, Henry R, Reichart D, Olefsky JM. Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. J Clin Endocrinol Metab. 1994; 78: 471-7
285. Klein HH, Vestergaard H, Kotzke G, Pedersen O. Elevation of serum insulin concentration during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in skeletal muscle of subjects with and without NIDDM. Diabetes. 1995; 44: 1310-7
286. Handberg A, Vaag A, Vinten J, Beck-Nielsen H. Decreased tyrosine kinase activity in partially purified insulin receptors from muscle of young, non-obese first degree relatives of patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1993; 36: 668-74
287. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest. 1995; 95: 2195-204
288. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes. 2003; 52: 1943-50
289. Kim YB, Kotani K, Ciaraldi TP, Henry RR, Kahn BB. Insulinstimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes. 2003; 52: 1935-42
290. Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, Kanoh Y, Powe J, Bandyopadhyay G, Standaert ML, Farese RV. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes. 2003; 52: 1926-34
291. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes. 2005; 54: 2351-9
292. Berria R, Wang L, Richardson DK, Finlayson J, Belfort R, Pratipanawatr T, De Filippis EA, Kashyap S, Mandarino LJ. Increased collagen content in insulin-resistant skeletal muscle. Am J Physiol Endocrinol Metab. 2006; 290: E560-5
293. Brozinick JT Jr, Roberts BR, Dohm GL. Defective signaling through Akt-2 and-3 but not Akt-1 in insulin-resistant human skeletal muscle: potential role in insulin resistance. Diabetes. 2003; 52: 935-41
294. Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, Cusi K. Discordant effects of a chronicphysiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab. 2004; 287: E537-46
295. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab. 2001; 281: E392-9
296. Klein HH, Muller R, Vestergaard H, Pedersen O. Implications of compound heterozygous insulin receptor mutations in congenital muscle fibre type disproportion myopathy for the receptor kinase activation. Diabetologia. 1999; 42: 245-9
297. Vestergaard H, Klein HH, Hansen T, Muller J, Skovby F, Bjorbak C, Roder ME, Pedersen O: Severe insulin-resistant diabetes mellitus in patients with congenital muscle fiber type disproportion myopathy. J Clin Invest. 95: 1925-1932, 1995
298. Krook A, Moller DE, Dib K, O'Rahilly S. Two naturally occurring mutant insulin receptors phosphorylate insulin receptor substrate-1 (IRS-1) but fail to mediate the biological effects of insulin. Evidence that IRS-1 phosphorylation is not sufficient for normal insulin action. J Biol Chem. 1996; 271: 7134-40
299. Krook A, Whitehead JP, Dobson SP, Griffiths MR, Ouwens M, Baker C, Hayward AC, Sen SK, Maassen JA, Siddle K, Tavare JM, O'Rahilly S. Two naturally occurring insulin receptor tyrosine kinase domain mutants provide evidence that phosphoinositide 3-kinase activation alone is not sufficient for the mediation of insulin's metabolic and mitogenic effects. J Biol Chem. 1997; 272: 30208-14
300. Krook A, Roth RA, Jiang XJ, Zierath JR, Wallberg-Henriksson H. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes. 1998; 47: 1281-6
301. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, Neschen S, White MF, Bilz S, Sono S, Pypaert M, Shulman GI. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest. 2005; 115: 3587-93
302. Cozzone D, Frojdo S, Disse E, Debard C, Laville M, Pirola L, Vidal H. Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients. Diabetologia. 2008; 51: 512-21
303. Tonks KT, Ng Y, Miller S, Coster AC, Samocha-Bonet D, Iseli TJ, Xu A, Patrick E, Yang JY, Junutula JR, et al. Impaired Akt phosphorylation in insulin-resistant human muscle is accompanied by selective and heterogeneous downstream defects. Diabetologia. 2013; 56: 875-85
304. Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB: Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes. 2002; 51:443-8
305. Meyer MM, Levin K, Grimmsmann T, Perwitz N, Eirich A, Beck-Nielsen H, Klein HH: Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Diabetes. 2002; 51: 2691-7
306. Karlsson HK, Hallsten K, Bjornholm M, Tsuchida H, Chibalin AV, Virtanen KA, Heinonen OJ, Lonnqvist F, Nuutila P, Zierath JR. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes. 2005; 54: 1459-67
307. Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab. 2009; 94: 157-63
308. Rajkhowa M, Brett S, Cuthbertson DJ, Lipina C, Ruiz-Alcaraz AJ, Thomas GE, Logie L, Petrie JR, Sutherland C. Insulin resistance in polycystic ovary syndrome is associated with defective regulation of ERK1/2 by insulin in skeletal muscle in vivo. Biochem J. 2009; 418: 665-71
309. Casaubon L, Sajan MP, Rivas J, Powe JL, Standaert ML, Farese RV. Contrasting insulin dose-dependent defects in activation of atypical protein kinase C and protein kinase B/Akt in muscles of obese diabetic humans. Diabetologia. 2006; 49: 3000-8
310. O'Gorman DJ, Karlsson HK, McQuaid S, Yousif O, Rahman Y, Gasparro D, Glund S, Chibalin AV, Zierath JR, Nolan JJ. Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes. Diabetologia. 2006; 49: 2983-92
311. Dohm GL, Tapscott EB, Pories WJ, Dabbs DJ, Flickinger EG, Meelheim D, Fushiki T, Atkinson SM, Elton CW, Caro JF. An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest. 1988; 82: 486-94
312. Ryder JW, Yang J, Galuska D, Rincon J, Bjornholm M, Krook A, Lund S, Pedersen O, Wallberg-Henriksson H, Zierath JR, Holman GD. Use of a novel impermeable biotinylated photolabeling reagent to assess insulin-and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients. Diabetes. 2000; 49: 647-54
313. Garvey WT, Maianu L, Zhu JH, Brechtel-Hook G, Wallace P, Baron AD. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest. 1998; 101: 2377-86
314. Zierath JR, He L, Guma A, Odegoard Wahlstrom E, Klip A, Wallberg-Henriksson H. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia. 1996; 39: 1180-9
315. Bostrom P, Andersson L, Rutberg M, Perman J, Lidberg U, Johansson BR, Fernandez-Rodriguez J, Ericson J, Nilsson T, Boren J, Olofsson SO. SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. Nat Cell Biol. 2007; 9: 1286-93
316. Bergman BC, Cornier MA, Horton TJ, Bessesen DH, Eckel RH. Skeletal muscle munc18c and syntaxin 4 in human obesity. Nutr Metab (Lond). 2008; 5: 21
317. Pehmoller C, Brandt N, Birk JB, Hoeg LD, Sjoberg KA, Goodyear LJ, Kiens B, Richter EA, Wojtaszewski JF. Exercise alleviates lipid-induced insulin resistance in human skeletal muscle-signaling interaction at the level of TBC1 domain family member 4. Diabetes. 2012; 61: 2743-52
318. Markuns JF, Wojtaszewski JFP, Goodyear LJ. Insulin and exercise decrease glycogen synthase kinase-3 activity by different mechanisms in rat skeletal muscle. J Biol Chem. 1999; 274: 24896-900
319. Wojtaszewski JFP, Nielsen P, Kiens B, Richter EA. Regulation of glycogen synthase kinase-3 in human skeletal muscle: effects of food intake and bicycle exercise. Diabetes. 2001; 50: 265-9
320. Friedrichsen M, Birk JB, Richter EA, Ribel-Madsen R, Pehmoller C, Hansen BF, Beck-Nielsen H, Hirshman MF, Goodyear LJ, Vaag A, Poulsen P, Wojtaszewski JF. Akt2 influences glycogen synthase activity in human skeletal muscle through regulation of NH2-terminal (sites 2 + 2a) phosphorylation. Am J Physiol Endocrinol Metab. 2013; 304: E631-9
321. Thorburn AW, Gumbiner B, Bulacan F, Brechtel G, Henry RR. Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest. 1991; 87: 489-95
322. Ortmeyer HK, Bodkin NL, Haney J, Yoshioka S, Horikoshi H, Hansen BC. A thiazolidinedione improves in vivo insulin action on skeletal muscle glycogen synthase in insulin-resistant monkeys. Int J Exp Diabetes Res. 2000; 1: 195-202
323. Damsbo P, Hermann LS, Vaag A, Hother-Nielsen O, Beck-Nielsen H. Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin. Diabetes Care. 1998; 21: 1489-94
324. Poulsen P, Wojtaszewski JF, Petersen I, Christensen K, Richter EA, Beck-Nielsen H, Vaag A. Impact of genetic versus environmental factors on the control of muscle glycogen synthase activation in twins. Diabetes. 2005; 54: 1289-96
325. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005; 26: 439-51
326. Whitehead JP, Richards AA, Hickman IJ, MacDonald GA, Prins JB. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006; 8: 264-280
327. Tishinsky JM, Dyck DJ, Robinson LE. Lifestyle factors increasing adiponectin synthesis and secretion. Vitam Horm. 2012; 90: 1-30
328. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003; 361: 226-228
329. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002; 360: 57-58
330. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005; 54: 534-9
331. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995; 270: 26746-9
332. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adiposespecific gene dysregulated in obesity. J Biol Chem. 1996; 271: 10697-703
333. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996; 221: 286-9
334. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001; 98: 2005-10
335. Bruce CR, Mertz VA, Heigenhauser GJ, Dyck DJ. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes. 2005; 54: 3154-60
336. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006; 55: 249-259
337. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004; 279: 12152-12162
338. Bluher M, Brennan AM, Kelesidis T, Kratzsch J, Fasshauer M, Kralisch S, Williams CJ & Mantzoros CS. Total and highmolecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care. 2007; 30: 280-285
339. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7: 941-6
340. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang C C, Itani SI, Lodish HF, Ruderman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A. 2002; 99: 16309-13
341. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes. 2006; 55: 2562-70
342. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8: 1288-95
343. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423: 762-9
344. Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S, Berria R, Belfort R, DeFronzo RA, Mandarino LJ, Ravussin E. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia. 2004; 47: 816-20
345. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012; 13: 251-62
346. Sanchez AM, Candau RB, Csibi A, Pagano AF, Raibon A, Bernardi H. The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and energy homeostasis. Am J Physiol Cell Physiol. 2012; 303: C475-85
347. Wojtaszewski JF, Birk JB, Frosig C, Holten M, Pilegaard H, Dela F. 5'AMP activated protein kinase expression in human skeletal muscle: effects of strength training and type 2 diabetes. J Physiol. 2005; 564: 563-73
348. Cartee GD, Wojtaszewski JF. Role of Akt substrate of 160 kDa in insulin-stimulated and contraction-stimulated glucose transport. Appl Physiol Nutr Metab. 2007; 32: 557-66
349. Bergeron R, Ren JM, Cadman KS, Moore IK, Perret P, Pypaert M, Young LH, Semenkovich CF, Shulman GI. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab. 2001; 281: E1340-6
350. Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman GI. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A. 2002; 99: 15983-7
351. Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy JO. Activation of AMP activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol. 2000; 88: 2219-26
352. Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol. 1999; 87: 1990-5
353. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013;17 185-96
354. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts CY, Hong JY, Kim RY, Liu F, Dong LQ. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006; 8: 516-23
355. Cleasby ME, Lau Q, Polkinghorne E, Patel SA, Leslie SJ, Turner N, Cooney GJ, Xu A, Kraegen EW. The adaptor protein APPL1 increases glycogen accumulation in rat skeletal muscle through activation of the PI3-kinase signalling pathway. J Endocrinol. 2011; 210: 81-92
356. Holmes RM, Yi Z, De Filippis E, Berria R, Shahani S, Sathyanarayana P, Sherman V, Fujiwara K, Meyer C, Christ-Roberts C, Hwang H, Finlayson J, Dong LQ, Mandarino LJ, Bajaj M. Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling. Diabetologia. 2011; 54: 2122-31
357. Patel SA, Hoehn KL, Lawrence RT, Sawbridge L, Talbot NA, Tomsig JL, Turner N, Cooney GJ, Whitehead JP, Kraegen EW, Cleasby ME. Overexpression of the adiponectin receptor AdipoR1 in rat skeletal muscle amplifies local insulin sensitivity. Endocrinology. 2012; 153: 5231-46
358. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, Yamaguchi M, Namiki S, Nakayama R, Tabata M, Ogata H, Kubota N, Takamoto I, Hayashi YK, Yamauchi N, Waki H, Fukayama M, Nishino I, Tokuyama K, Ueki K, Oike Y, Ishii S, Hirose K, Shimizu T, Touhara K, Kadowaki T. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010; 464: 1313-9
359. Wang C, Mao X, Wang L, Liu M, Wetzel MD, Guan KL, Dong LQ, Liu F. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem. 2007; 282: 7991-6
360. Cesari M, Narkiewicz K, De Toni R, Aldighieri E, Williams CJ, Rossi GP. Heritability of plasma adiponectin levels and body mass index in twins. J Clin Endocrinol Metab. 2007; 92: 3082-8
361. Liu PH, Jiang YD, Chen WJ, Chang CC, Lee TC, Sun HS, Chuang LM. Genetic and environmental influences on adiponectin, leptin, and BMI among adolescents in Taiwan: a multivariate twin/sibling analysis. Twin Res Hum Genet. 2008; 11: 495-504
362. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes. 2007; 56: 1198-1209
363. Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA, Henneman P, Heid IM, Kizer JR, Lyytikainen LP, et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 2012; 8: e1002607
364. Richards JB, Waterworth D, O'Rahilly S, Hivert MF, Loos RJ, Perry JR, Tanaka T, Timpson NJ, Semple RK, Soranzo N, et al. A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet. 2009; 5: e1000768
365. Breitfeld J, Stumvoll M, Kovacs P. Genetics of adiponectin. Biochimie. 2012; 94: 2157-63
366. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86: 1930-5
367. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002; 51: 2968-4
368. Salmenniemi U, Zacharova J, Ruotsalainen E, Vauhkonen I, Pihlajamaki J, Kainulainen S, Punnonen K, Laakso M. Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure, and cytokines in offspring of type 2 diabetic patients. J Clin Endocrinol Metab. 2005; 90: 4216-23
369. Lattuada G, Costantino F, Caumo A, Scifo P, Ragogna F, De Cobelli F, Del Maschio A, Luzi L, Perseghin G. Reduced wholebody lipid oxidation is associated with insulin resistance, but not with intramyocellular lipid content in offspring of type 2 diabetic patients. Diabetologia. 2005; 48: 741-7
370. Kowalska I, Straczkowski M, Nikolajuk A, Krukowska A, Kinalska I, Gorska M. Plasma adiponectin concentration and tumor necrosis factor-alpha system activity in lean nondiabetic offspring of type 2 diabetic subjects. Eur J Endocrinol. 2006; 154: 319-24
371. Pellme F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O, Taskinen MR, Jansson PA. Circulating adiponectin levels are reduced in nonobese but insulin-resistant firstdegree relatives of type 2 diabetic patients. Diabetes. 2003; 52: 1182-6
372. Lihn AS, Ostergard T, Nyholm B, Pedersen SB, Richelsen B, Schmitz O. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2003; 284: E443-8
373. Johanson EH, Jansson PA, Lonn L, Matsuzawa Y, Funahashi T, Taskinen MR, Smith U, Axelsen M. Fat distribution, lipid accumulation in the liver, and exercise capacity do not explain the insulin resistance in healthy males with a family history for type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 4232-8
374. Ardawi MS, Rouzi, AA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2005; 83: 1708-16
375. Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A, Hermann AP. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol. 2006; 155: 337-45
376. Sepilian V, Nagamani M. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance. J Soc Gynecol Investig. 2005; 12: 129-34
377. Sieminska L, Marek B, Kos-Kudla B, Niedziolka D, Kajdaniuk D, Nowak M, Glogowska-Szelag J. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest. 2004; 27: 528-34
378. Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, Lombardi G, Lobo RA. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005; 152: 389-94
379. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R, Kadowaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006; 29: 1357-62
380. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010; 316: 129-39
381. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, Flyvbjerg A, Walker M, Hojlund K, Nolan JJ & European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk Study Group), Savage DB. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009; 52: 2345-9
382. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005; 257: 167-75
383. Maddux BA, Chan A, De Filippis EA, Mandarino LJ, Goldfine ID. IGF-binding protein-1 levels are related to insulinmediated glucose disposal and are a potential serum marker of insulin resistance. Diabetes Care. 2006; 29: 1535-7
384. Arafat AM, Weickert MO, Frystyk J, Spranger J, Schofl C, Mohlig M, Pfeiffer AF. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab. 2009; 94: 5093-101
385. Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG, Gibson JM. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes. 2006; 114: 371-6
386. Cook JR, Semple RK. Hypoadiponectinemia--cause or consequence of human insulin resistance? J Clin Endocrinol Metab. 2010; 95: 1544-54
387. Semple RK, Soos MA, Luan J, Mitchell CS, Wilson JC, Gurnell M, Cochran EK, Gorden P, Chatterjee VK, Wareham NJ, O'Rahilly S. Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab. 2006; 91: 3219-23
388. Semple RK, Cochran EK, Soos MA, Burling KA, Savage DB, Gorden P, O'Rahilly S. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care. 2008; 31: 977-79
389. Mohlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF, Spranger J. Insulin decreases human adiponectin plasma levels. Horm Metab Res. 2002; 34: 655-8
390. Leth H, Andersen KK, Frystyk J, Tarnow L, Rossing P, Parving HH, Flyvbjerg A. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab. 2008; 93: 3186-91
391. Drapeau S, Doucet E, Rabasa-Lhoret R, Brochu M, Prud'homme D, Imbeault P. Improvement in insulin sensitivity by weight loss does not affect hyperinsulinemia-mediated reduction in total and high molecular weight adiponectin: a MONET study. Appl Physiol Nutr Metab. 2011; 36: 191-200
392. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002; 51: 18848
393. Yokoyama H, Emoto M, Mori K, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y. Plasma adiponectin level is associated with insulin-stimulated nonoxidative glucose disposal. J Clin Endocrinol Metab. 2006; 91: 290-4
394. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004; 89: 200-6
395. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Haring H, Stumvoll M. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003; 52: 239-43
396. Adamska A, Nikołajuk A, Karczewska-Kupczewska M, Kowalska I, Otziomek E, Gorska M, Straczkowski M. Relationships between serum adiponectin and soluble TNF-α receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol. 2012; 49: 17-24
397. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, Kesaniemi YA, Tapanainen JS, Ukkola O, Morin-Papunen L. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol. 2007; 156: 263-9
398. Manneras-Holm L, Leonhardt H, Kullberg J, Jennische E, Oden A, Holm G, Hellstrom M, Lonn L, Olivecrona G, Stener-Victorin E, Lonn M. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011; 96: E304-11
399. Civitarese AE, Ukropcova B, Carling S, Hulver M, DeFronzo RA, Mandarino L, Ravussin E, Smith SR. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab. 2006; 4: 75-87
400. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M. Mechanisms of early insulinsensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes. 2004; 53: 1621-9
401. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004; 89: 4312-9
402. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance inpioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004; 89: 200-6
403. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004; 53: 2169-76
404. Boden G, Cheung P, Mozzoli M, Fried SK. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism. 2003; 52: 753-9
405. Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia. 2009; 52: 723-32
406. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes. 2006; 55: 2277-85
407. Hoeg LD, Sjoberg KA, Lundsgaard AM, Jordy AB, Hiscock N, Wojtaszewski JF, Richter EA, Kiens B. Adiponectin concentration is associated with muscle insulin sensitivity, AMPK phosphorylation, and ceramide content in skeletal muscles of men but not women. J Appl Physiol. 2013; 114: 592-601
408. Musi N, Fujii N, Hirshman MF, Ekberg I, Froberg S, Ljungqvist O, Thorell A, Goodyear LJ. AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes. 2001; 50: 921-7
409. Steinberg GR, Smith AC, Van Denderen BJ, Chen Z, Murthy S, Campbell DJ, Heigenhauser GJ, Dyck DJ, Kemp BE. AMPactivated protein kinase is not down-regulated in human skeletal muscle of obese females. J Clin Endocrinol Metab. 2004; 89: 4575-80
410. Koistinen HA, Galuska D, Chibalin AV, Yang J, Zierath JR, Holman GD, Wallberg-Henriksson H. 5-amino-imidazole carboxamide riboside increases glucose transport and cellsurface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes. 2003; 52: 1066-72
411. Prats C, Gomez-Cabello A, Hansen AV. Intracellular compartmentalization of skeletal muscle glycogen metabolism and insulin signalling. Exp Physiol. 2011; 96: 385-90
412. He C, Bassik MC, Moresi V, Sun K, Wei Y, Zou Z, An Z, Loh J, Fisher J, Sun Q, Korsmeyer S, Packer M, May HI, Hill JA, Virgin HW, Gilpin C, Xiao G, Bassel-Duby R, Scherer PE, Levine B. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature. 2012; 481: 511-5
413. Kim KH, Jeong YT, Oh H, Kim SH, Cho JM, Kim YN, Kim SS, Kim do H, Hur KY, Kim HK, Ko T, Han J, Kim HL, Kim J, Back SH, Komatsu M, Chen H, Chan DC, Konishi M, Itoh N, Choi CS, Lee MS. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med. 2013; 19: 83-92
414. Wu J, Ruas JL, Estall JL, Rasbach KA, Choi JH, Ye L, Bostrom P, Tyra HM, Crawford RW, Campbell KP, Rutkowski DT, Kaufman RJ, Spiegelman BM. The unfolded protein response mediates adaptation to exercise in skeletal muscle through a PGC-1α/ATF6α complex. Cell Metab. 2011; 13: 160-9
415. Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A. 2007; 104: 5860-5
416. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods. 2012; 9: 555-66.